10x Genomics, Inc. , a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
10x Genomics stock last closed at $52.88, up 3.2% from the previous day, and has increased 11.68% in one year. It has overperformed other stocks in the Health Information Services industry by 0.32 percentage points. 10x Genomics stock is currently +122.09% from its 52-week low of $23.81, and -9.29% from its 52-week high of $58.30.
At the moment, there are 116.19M shares of TXG outstanding. The market cap of TXG is $6.14B. In the last 24 hours, 719,259 TXG shares were traded.
You will need an online brokerage account to access the NASDAQ market and buy TXG shares.
Based on our experience, eToro is the best place to buy stocks. eToro gives you:
Get $10 towards your stock purchase by creating an account with eToro today.
Open eToro AccountNow that you've selected the right brokerage, you need to fill out some personal info so you can buy TXG stock today.
Now that you've filled out your info on stock market apps, you can securely and quickly fund your account:
Watch the walkthrough below for more details depositing funds into your brokerage account.
Once you have selected the best place to buy 10x Genomics stock, it's important to research their stock prior to investing, so you can understand the risk as well as the upside.
WallStreetZen was built to help everyday investors perform better fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on TXG's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge TXG's intrinsic value.
Using relative valuations metrics:
You can do more valuation research on TXG's stock here.
Out of 8 sell side analysts who research TXG, the consensus analyst rating on TXG is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they investment advice.
Mason Carrico, a bottom 4% analyst from Stephens & Co. reiterates TXG with a strong buy rating and maintains their TXG price target from $65.00 to $65.00, on May 18, 2023.
Luke Sergott, a bottom 2% analyst from Barclays initiates coverage on TXG with a strong buy rating and announces their TXG price target of $65.00, on May 10, 2023.
Daniel Arias, a top 9% analyst from Stifel Nicolaus maintains TXG with a strong buy rating and raises their TXG price target from $57.00 to $68.00, on May 4, 2023.
Maintaining his Strong Buy rating, Arias raised his price target on 10x Genomics, Inc. by 19.3% following the release of the company's Q1 2023 earnings report on 2023/05/03.
10x Genomics' kicked off FY 2023 with a "solid" print, the analyst summarized.
The revenue beat was "largely expected," but management's guidance raise did not meet analysts' expectations, Arias detailed.
While China was, for the most part, down, the analyst argued that, overall, the set-up for 10x Genomics remains positive in terms of further upside."
The stock is up 41.8% YTD against the S&P 500's 7.3% gain.
For Q1 2023, 10x Genomics reported:
For FY 2023, management guided:
Co-founder & CEO Serge Saxonov commented: "We are proud of our solid start to the year, fueled by strong performance across our spatial portfolio and a return to double-digit growth in single-cell consumables.
"We are energized by the momentum and traction we're seeing with Xenium* in its first full quarter of launch; the overwhelmingly positive feedback from our early customers reinforces our belief that Xenium is the best In Situ platform on the market."
* From here: Xenium is an instrument that spatially profiles genes and proteins at subcellular resolution. Xenium enables subcellular mapping of hundreds of RNA targets, generating high-quality data with high sensitivity and specificity to reveal insights into cellular structure and function."
Dan Brennan, a top 16% analyst from TD Cowen maintains TXG with a buy rating and raises their TXG price target from $62.00 to $66.00, on May 4, 2023.
Kyle Mikson, a bottom 3% analyst from Canaccord Genuity maintains TXG with a strong buy rating and raises their TXG price target from $58.00 to $65.00, on May 4, 2023.
You can dig deeper into what analysts are forecasting on the 10x Genomics stock forecast page.
Last year, TXG revenue was $536.20M. In the last 3 year, TXG's revenue has grown by 100.97% per year. This was faster than the Health Information Services industry average of 48.97%.
You can research TXG's earnings and revenue performance here.
In the past year, executives and large shareholders at TXG have bought more shares than they have sold.
Benjamin J. Hindson, President and Chief Scientific Officer of TXG, was the latest TXG insider to sell. They sold $34,082.14 worth of TXG stock on May 23, 2023.
Get more info about who owns TXG stock here.
No, 10x Genomics doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
You have two primary options:
Click the Open Trade button and eToro will execute the order.
If you want more help buying stocks on eToro, click the how to video below:
Now that you own some shares in TXG, you'll want to keep up with your shares.
Start a watchlist to get alerted to the latest events about your TXG stock.
To summarize, here are the 6 steps to buy stock in 10x Genomics:
If you require a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you would like to get notifications regarding your new investment in 10x Genomics, click below.